SynthesisClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2023
Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Synthesis in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial.Rheumatology international · 2026Trial
- DAS28-ESR may underestimate disease activity in rheumatoid arthritis patients with nonalcoholic fatty liver disease: a retrospective cohort study.Arthritis research & therapy · 2026Article
- Metabolic and Anthropometric Alterations in Juvenile Idiopathic Arthritis: A Focus on Cardiometabolic Risk and Non-Invasive Evaluation Methods.Metabolites · 2026Review
- A Shared EGR1-IL-32-Macrophage Polarisation Signature in Rheumatoid Arthritis and Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of inflammation research · 2026Article
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.Journal of clinical pharmacology · 2025Article
- Autoimmunity in MASLD: Focus on autoantibodies, anti-apolipoprotein A1 IgG and G protein-coupled receptors.European journal of clinical investigation · 2025Review
- Methotrexate and biological therapy are not associated with fatty liver in rheumatoid arthritis-a cross-sectional study.Rheumatology international · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis.Clinical rheumatology · 2025Article
- Correlates of oral health-related quality of life in a sample of patients with rheumatoid arthritis.BMC oral health · 2025Article
- Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD.ImmunoTargets and therapy · 2025Review
- Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- A cross sectional study assessing steatotic liver disease in patients with systemic lupus erythematosus.Scientific reports · 2024Article
- Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.Digestive diseases and sciences · 2024Article
- Oxidative balance score and the potential for suffering rheumatoid arthritis: a cross-sectional study.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsPrevious studies have shown a potential association between nonalcoholic fatty liver disease (NAFLD) and some immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), but this association has not been analyzed systematically. Therefore, we aimed to perform a systematic review and meta-analysis to ascertain a pooled prevalence estimate of NAFLD among patients with RA to fill this gap in knowledge.
methodsWe conducted a literature search in PubMed, Embase, Web of Science, Scopus, and ProQuest, for observational studies published from inception to August 31, 2022, which reported prevalence of NAFLD in 100 or more adult (age, ≥18 y) patients with RA. To be included, NAFLD diagnosis was based on either imaging or histologic assessment. The results were presented as pooled prevalence, odds ratio, and 95% CI. The I
resultsThis systematic review included 9 eligible studies derived from 4 continents comprising 2178 patients (78.8% women) with RA. The pooled prevalence of NAFLD was 35.3% (95% CI, 19.9-50.6; I
conclusionsBased on this meta-analysis, 1 in 3 patients with RA had NAFLD, which appears comparable with its overall prevalence among the general population. Clinicians should actively screen for NAFLD in patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.